(E)-Daporinad [658084-64-1]

Katalog-Nummer NB-64-15615-5mg

Size : 5mg

Marke : Neo Biotech

Contact local distributor :


Telefonnummer : +1 850 650 7790

(E)-Daporinad

Alias FK866, Daporinad, APO866, (E)-N-[4-(1-BENZOYL-PIPERIDIN-4-YL)-BUTYL]-3-PYRIDIN-3-YL-ACRYLAMIDE

(E)-Daporinad (FK866) is a highly specific, non-competitive small molecule inhibitor of nicotinamide phosphoribosyltransferase (NAMPT) with potential anti-tumor and anti-angiogenic activities with an IC50 value of 0.09 nM.

(E)-Daporinad
Select Batch
Purity:99.55%
Contact us for more batch information

Product Introduction

Bioactivity
Description
(E)-Daporinad (FK866) is a highly specific, non-competitive small molecule inhibitor of nicotinamide phosphoribosyltransferase (NAMPT) with potential anti-tumor and anti-angiogenic activities with an IC50 value of 0.09 nM.
Targets&IC50
NAMPT:0.09 nM, NMPRTase:0.4 nM (Ki)
In vitro
METHODS: Hepatocytes were pretreated with (E)-Daporinad( FK866 ) (100 nM, 30 minutes) and then challenged with GaIN/LPS (G/L, 1 mg/mL /30 ng/mL, 24 hours) to observe whether (E)-Daporinad( FK866 ) could alleviate GaIN/LPS-induced hepatotoxicity.
RESULTS Primary hepatocytes pretreated with (E)-Daporinad( FK866 ) showed a significant increase in autophagic activity after GaIN/LPS injury. (E)-Daporinad( FK866 ) could improve liver injury induced by GaIN/LPS and ConA. Its protective mechanism may involve its ability to induce autophagy by inhibiting JNK. [1]
In vivo
METHODS: (E)-Daporinad( FK866 )(10 mg/kg, intraperitoneal injection) was administered to mice 24, 12, and 0.5 hours before treatment with GaIN/LPS and ConA to test the potential effect of (E)-Daporinad( FK866 ) on ALF in mice.
RESULTS (E)-Daporinad( FK866 ) treatment reduced the mortality of mice treated with GaIN/LPS or ConA. (E)-Daporinad( FK866 ) treatment before and after treatment attenuated GaIN/LPS and ConA-induced ALF in mice, and (E)-Daporinad( FK866 ) pretreatment resulted in a better response to GaIN/LPS or ConA challenge. [1]
Kinase Assay
High Throughput Screening: FITC-MBM1 at 15 nM and menin at 150 nM in the FP buffer are mixed and incubated for 1h in the dark at room temperature. For point screening, the 0.2 μL of each compound (20 μM final concentration, 1% DMSO) is added to 20 μL of the aliquot of the protein-peptide mixture and incubated on 384-well plates in the dark at room temperature for 1h. In confirmation screening, the serial dilution plates with compounds in DMSO are prepared and used to titrate the menin-FITC-MBM1 complex. Change in fluorescence polarization is monitored at 525 nm after excitations at 495 nm using the PHERAstar microplate reader (BMG) and applied to determine IC50 values with the Origin 7.0 program.
Cell Research
For MTT assays, 0.5 × 106 cells/mL is plated in triplicate on 96-well plates. APO866 (0.01 nM-100 nM) is added in 50 μL of culture medium, with culture medium alone serving as control. After 72 or 96 hours of incubation, 15 μL of dye solution is added to each well and cells are incubated for an additional 4 hours. Stop solution (100 μL/well) is added for 1 hour and the absorbance is read at 570 nm on a spectrophotometer. For trypan blue dye exclusion staining, 0.5 × 105 cells/well is grown in 6-well plates with 1 mL media in the absence or presence of APO866 for 96 hours. Cells from each sample are incubated with 10 μL trypan blue solution (at a 1:1 ratio [vol/vol] for 1 minute). Cell survival is determined by calculating proportion of live (unstained) cells. (Only for Reference)
SynonymsFK866, Daporinad, APO866, (E)-N-[4-(1-BENZOYL-PIPERIDIN-4-YL)-BUTYL]-3-PYRIDIN-3-YL-ACRYLAMIDE
Chemical Properties
Molecular Weight391.51
FormulaC24H29N3O2
Cas No.658084-64-1
SmilesC(=O)(N1CCC(CCCCNC(/C=C/C=2C=CC=NC2)=O)CC1)C3=CC=CC=C3
Relative Density.1.131 g/cm3
ColorWhite
AppearanceSolid
Storage & Solubility Information
Storagestore at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 257.5 mg/mL (657.71 mM), Sonication is recommended.
Ethanol: 72 mg/mL (183.9 mM), Sonication is recommended.
In Vivo Formulation
10% DMSO+90% Saline: 0.1 mg/mL (0.26 mM), Solution.
Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.
Solution Preparation Table
Ethanol/DMSO
1mg5mg10mg50mg
1 mM2.5542 mL12.7711 mL25.5421 mL127.7107 mL
5 mM0.5108 mL2.5542 mL5.1084 mL25.5421 mL
10 mM0.2554 mL1.2771 mL2.5542 mL12.7711 mL
20 mM0.1277 mL0.6386 mL1.2771 mL6.3855 mL
50 mM0.0511 mL0.2554 mL0.5108 mL2.5542 mL
100 mM0.0255 mL0.1277 mL0.2554 mL1.2771 mL

Sie könnten auch an folgenden Produkten interessiert sein:



Katalog-Nummer
Beschreibung
Cond.
Preis zzgl. MwSt.
PB180426-100
 100mL 
HY-50876-5mg
 5mg 
HY-50876-50mg
 50mg